tbuckley/cabot-search huggingface dataset:
Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations
Authors: Jess F. Peterson, Ross A. Rowsey, Cherisse A. Marcou, Kathryn E. Pearce, Cynthia M. Williamson, Lori A. Frederick, Patricia T. Greipp, Rhett P. Ketterling, Shaji Kumar, David S. Viswanatha, Mei-Yin Polley, James M. Fink, Kaaren K. Reichard, Daniel L. Van Dyke, Linda B. Baughn
Journal: Blood Cancer Journal (2019)
Breast cancer statistics, 2011
Authors: Carol DeSantis, Rebecca Siegel, Priti Bandi, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2011)

Abstract In this article, the American Cancer Society provides an overview of female breast cancer statistics in the United States, including trends in incidence, mortality, survival, and screening. Approximately 230,480 new cases of invasive breast cancer and 39,520 breast cancer deaths are expected to occur among US women in 2011. Breast cancer incidence rates were stable among all racial/ethnic groups from 2004 to 2008. Breast cancer death rates have been declining since the early 1990s for all women except American Indians/Alaska Natives, among whom rates have remained stable. Disparities in breast cancer death rates are evident by state, socioeconomic status, and race/ethnicity. While significant declines in mortality rates were observed for 36 states and the District of Columbia over the past 10 years, rates for 14 states remained level. Analyses by county‐level poverty rates showed that the decrease in mortality rates began later and was slower among women residing in poor areas. As a result, the highest breast cancer death rates shifted from the affluent areas to the poor areas in the early 1990s. Screening rates continue to be lower in poor women compared with non‐poor women, despite much progress in increasing mammography utilization. In 2008, 51.4% of poor women had undergone a screening mammogram in the past 2 years compared with 72.8% of non‐poor women. Encouraging patients aged 40 years and older to have annual mammography and a clinical breast examination is the single most important step that clinicians can take to reduce suffering and death from breast cancer. Clinicians should also ensure that patients at high risk of breast cancer are identified and offered appropriate screening and follow‐up. Continued progress in the control of breast cancer will require sustained and increased efforts to provide high‐quality screening, diagnosis, and treatment to all segments of the population. CA Cancer J Clin 2011;. © 2011 American Cancer Society.
A Novel Bone Substitute with High Bioactivity, Strength, and Porosity for Repairing Large and Load‐Bearing Bone Defects
Authors: Jiao Jiao Li, Colin R. Dunstan, Ali Entezari, Qing Li, Roland Steck, Siamak Saifzadeh, Ameneh Sadeghpour, John R. Field, Austin Akey, Martin Vielreicher, Oliver Friedrich, Seyed‐Iman Roohani‐Esfahani, Hala Zreiqat
Journal: Advanced Healthcare Materials (2019)

Abstract Achieving adequate healing in large or load‐bearing bone defects is highly challenging even with surgical intervention. The clinical standard of repairing bone defects using autografts or allografts has many drawbacks. A bioactive ceramic scaffold, strontium‐hardystonite‐gahnite or “Sr‐HT‐Gahnite” (a multi‐component, calcium silicate‐based ceramic) is developed, which when 3D‐printed combines high strength with outstanding bone regeneration ability. In this study, the performance of purely synthetic, 3D‐printed Sr‐HT‐Gahnite scaffolds is assessed in repairing large and load‐bearing bone defects. The scaffolds are implanted into critical‐sized segmental defects in sheep tibia for 3 and 12 months, with bone autografts used for comparison. The scaffolds induce substantial bone formation and defect bridging after 12 months, as indicated by X‐ray, micro‐computed tomography, and histological and biomechanical analyses. Detailed analysis of the bone‐scaffold interface using focused ion beam scanning electron microscopy and multiphoton microscopy shows scaffold degradation and maturation of the newly formed bone. In silico modeling of strain energy distribution in the scaffolds reveal the importance of surgical fixation and mechanical loading on long‐term bone regeneration. The clinical application of 3D‐printed Sr‐HT‐Gahnite scaffolds as a synthetic bone substitute can potentially improve the repair of challenging bone defects and overcome the limitations of bone graft transplantation.
Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne
Authors: Jerry Tan, Diane Thiboutot, Georg Popp, Melinda Gooderham, Charles Lynde, James Del Rosso, Jonathan Weiss, Ulrike Blume-Peytavi, Jolanta Weglovska, Sandra Johnson, Lawrence Parish, Dagmara Witkowska, Nestor Sanchez Colon, Alessandra Alió Saenz, Faiz Ahmad, Michael Graeber, Linda Stein Gold
Journal: Journal of the American Academy of Dermatology (2019)

Acne vulgaris often affects the face, shoulders, chest, and back, but treatment of nonfacial acne has not been rigorously studied.Assess the safety and efficacy of trifarotene 50 μg/g cream, a novel topical retinoid, in moderate facial and truncal acne.Two phase III double-blind, randomized, vehicle-controlled, 12-week studies of once-daily trifarotene cream versus vehicle in subjects aged 9 years or older. The primary end points were rate of success on the face, as determined by the Investigator's Global Assessment (clear or almost clear and ≥2-grade improvement), and absolute change from baseline in inflammatory and noninflammatory counts from baseline to week 12. The secondary end points were rate of success on the trunk (clear or almost clear and ≥2-grade improvement) and absolute change in truncal inflammatory and noninflammatory counts from baseline to week 12. Safety was assessed through adverse events, local tolerability, vital signs, and routine laboratory testing results.In both studies, at week 12 the facial success rates according to the Investigator's Global Assessment and truncal Physician's Global Assessment and change in inflammatory and noninflammatory lesion counts (both absolute and percentage) were all highly significant (P < .001) in favor of trifarotene when compared with the vehicle.Adjunctive topical or systemic treatments were not studied.These studies demonstrate that trifarotene appears to be safe, effective, and well tolerated in treatment of both facial and truncal acne.
Subtherapeutic posaconazole troughs despite high-dose posaconazole tablets in a patient with terminal ileum resection
Authors: Peijun Yvonne Zhou, Tze Peng Lim, Si Lin Sarah Tang, Hui Ling Winnie Lee, Thuan Tong Tan, Ban Hock Tan, Si Yun Melinda Tan, Gee Chuan Wong, Lay Hoon Andrea Kwa
Journal: Journal of Infection (2019)
Evaluation of Access to Hospitals Most Ready to Achieve National Accreditation for Rectal Cancer Treatment
Authors: Alexis G. Antunez, Arielle E. Kanters, Scott E. Regenbogen
Journal: JAMA Surgery (2019)

The American College of Surgeons National Accreditation Program for Rectal Cancer (NAPRC) promotes multidisciplinary care to improve oncologic outcomes in rectal cancer. However, accreditation requirements may be difficult to achieve for the lowest-performing institutions. Thus, it is unknown whether the NAPRC will motivate care improvement in these settings or widen disparities.To characterize hospitals' readiness for accreditation and identify differences in the patients cared for in hospitals most and least prepared for accreditation.A total of 1315 American College of Surgeons Commission on Cancer-accredited hospitals in the National Cancer Database from January 1, 2011, to December 31, 2015, were sorted into 4 cohorts, organized by high vs low volume and adherence to process standards, and patient and hospital characteristics and oncologic outcomes were compared. The patients included those who underwent surgical resection with curative intent for rectal adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma. Data analysis was performed from November 2017 to January 2018.Hospitals' readiness for accreditation, as determined by their annual resection volume and adherence to 5 available NAPRC process standards.Hospital characteristics, patient sociodemographic characteristics, and 5-year survival by hospital.Among the 1315 included hospitals, 38 (2.9%) met proposed thresholds for all 5 NAPRC process standards and 220 (16.7%) met the threshold on 4 standards. High-volume hospitals (≥20 resections per year) tended to be academic institutions (67 of 104 [64.4%] vs 159 of 1211 [13.1%]; P = .001), whereas low-volume hospitals (<20 resections per year) tended to be comprehensive community cancer programs (530 of 1211 [43.8%] vs 28 of 104 [26.9%]; P = .001). Patients in low-volume hospitals were more likely to be older (11 429 of 28 076 [40.7%] vs 4339 of 12 148 [35.7%]; P < .001) and have public insurance (13 054 of 28 076 [46.5%] vs 4905 of 12 148 [40.4%]; P < .001). Low-adherence hospitals were more likely to care for black and Hispanic patients (1980 of 19 577 [17.2%] vs 3554 of 20 647 [10.1%]; P < .001). On multivariable Cox proportional hazards model regression, high-volume hospitals had better 5-year survival outcomes than low-volume hospitals (hazard ratio, 0.99; 95% CI, 0.99-1.00; P < .001), but there was no significant survival difference by hospital process standard adherence.Hospitals least likely to receive NAPRC accreditation tended to be community institutions with worse survival outcomes, serving patients at a lower socioeconomic position. To possibly avoid exacerbating disparities in access to high-quality rectal cancer care, the NAPRC study findings suggest enabling access for patients with socioeconomic disadvantage or engaging in quality improvement for hospitals not yet achieving accreditation benchmarks.
Significance of ischemic heart disease in patients with heart failure with preserved, mid-range and reduced ejection fraction - A nationwide cohort study
Authors: Ola Vedin, C. S. P. Lam, A. S. Koh, L. Benson, T. H. K. Teng, W. T. Tay, O. O. Braun, G. Savarese, U. Dahlstrom, L. H. Lund
Journal: European Journal of Heart Failure (2017)
Loss-of-Function Mutations in HLA-Class I Alleles in Acquire Aplastic Anemia: Evidence for the Involvement of Limited Class I Alleles in the Auto-Antigen Presentation of Aplastic Anemia
Authors: Hiroki Mizumaki, Kazuyoshi Hosomichi, Tanabe Mikoto, Takeshi Yoroidaka, Tatsuya Imi, Yoshitaka Zaimoku, Kohei Hosokawa, Takamasa Katagiri, Hiroyuki Takamatsu, Tatsuhiko Ozawa, Fumihiro Azuma, Hiroyuki Kishi, Atsushi Tajima, Shinji Nakao
Journal: Blood (2018)
Executive Summary: Heart Disease and Stroke Statistics—2011 Update
Authors: Véronique L. Roger, Alan S. Go, Donald M. Lloyd-Jones, Robert J. Adams, Jarett D. Berry, Todd M. Brown, Mercedes R. Carnethon, Shifan Dai, Giovanni de Simone, Earl S. Ford, Caroline S. Fox, Heather J. Fullerton, Cathleen Gillespie, Kurt J. Greenlund, Susan M. Hailpern, John A. Heit, P. Michael Ho, Virginia J. Howard, Brett M. Kissela, Steven J. Kittner, Daniel T. Lackland, Judith H. Lichtman, Lynda D. Lisabeth, Diane M. Makuc, Gregory M. Marcus, Ariane Marelli, David B. Matchar, Mary M. McDermott, James B. Meigs, Claudia S. Moy, Dariush Mozaffarian, Michael E. Mussolino, Graham Nichol, Nina P. Paynter, Wayne D. Rosamond, Paul D. Sorlie, Randall S. Stafford, Tanya N. Turan, Melanie B. Turner, Nathan D. Wong, Judith Wylie-Rosett
Journal: Circulation (2011)
Untethering Idea Generation From Protocol Execution in Neurorehabilitation Research
Authors: Noam Yehezkel Harel
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Signaling Regulatory Protein (SIRP)α-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition
Authors: André Veillette, Zhenghai Tang
Journal: Journal of Clinical Oncology (2019)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. February 27, 2019 ARTICLE CITATION DOI: 10.1200/JCO.19.00121 Journal of Clinical Oncology - published online before print February 27, 2019 PMID: 30811295 Signaling Regulatory Protein (SIRP)α-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition André Veillette, MD1,2,3xAndré VeilletteSearch for articles by this author and Zhenghai Tang, PhD1xZhenghai TangSearch for articles by this author Show More 1Institut de Recherches Cliniques de Montréal, Montréal, Quebec, Canada2University of Montréal, Montréal, Quebec, Canada3McGill University, Montréal, Quebec, Canada https://doi.org/10.1200/JCO.19.00121 First Page Full Text PDF Figures and Tables © 2019 by American Society of Clinical Oncology Companion First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Sarah Wollaston: I’ll keep providing scrutiny, says newly independent MP
Authors: Harriet Pike
Journal: BMJ (2019)

Former GP Sarah Wollaston will remain as chair of the health select committee after her resignation from the Conservative Party.

The member for Totnes, the first MP to have been elected after an “open primary” in which voting for selection as a candidate was open to the public, not just party members, announced her decision to leave the Tories on 20 February 2019, along with Heidi Allen and Anna Soubry. They have joined a newly formed group of independent MPs created by seven MPs who resigned from the Labour Party on 18 February.

Wollaston’s decision to resign the Conservative Party whip and to join the Independent Group does not affect her position as chair of the House of Commons Health and Social Care Committee.

“Select committee chairs are elected by the whole House of Commons—they are not appointed,” Wollaston told The BMJ . “I will remain as chair unless the committee decides that it no longer has confidence in me.”

Wollaston said that her resignation from the Conservative Party would not change the way she chairs the health committee. “Select committee chairs are …
Are There Upper Limits in Tumor Burden for Down‐Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All‐Comers Protocol
Authors: Jasmine Sinha, Neil Mehta, Jennifer L. Dodge, Eduard Poltavskiy, John Roberts, Francis Yao
Journal: Hepatology (2019)

Patients with hepatocellular carcinoma (HCC) within the University of California, San Francisco down‐staging (UCSF‐DS) criteria (one lesion &gt; 5 cm and ≤ 8 cm; two to three lesions each ≤ 5 cm; or four to five lesions each ≤ 3 cm with total tumor diameter ≤ 8 cm) who achieved successful down‐staging (DS) to Milan criteria had similar outcomes after liver transplantation (LT) compared with HCC initially meeting the Milan criteria. Nevertheless, little is known about the outcome of DS in patients with initial tumor burden exceeding the UCSF‐DS criteria, defined as “all‐comers” (AC). We compared the intention‐to‐treat (ITT) outcomes of DS in 74 patients in the AC group and 133 patients in the UCSF‐DS group. Successful DS to Milan was observed in 64.8% of the AC group versus 84.2% of the UCSF‐DS group ( P &lt; 0.001). The sum of tumor number and largest tumor diameter was significantly associated with successful DS (hazard ratio [HR] 0.87, P &lt; 0.05). The cumulative probability of dropout within 1 year and 3 years was 53.5% and 80.0%, respectively, for AC versus 25.0% and 36.1%, respectively, for UCSF‐DS ( P &lt; 0.0001). Factors predicting dropout included sum of tumor number and largest tumor diameter greater than 8 (HR 1.79, P = 0.049) and Child class B and C (HR 2.54, P = 0.001). The AC group also had a significantly lower liver transplant (LT) rate (13.5% versus 59.0%, P &lt; 0.001). ITT survival at 1 year and 5 years was 77.4% and 21.1%, respectively, in AC versus 85.5% and 56.0%, respectively, in UCSF‐DS ( P &lt; 0.001). Three of 10 patients in the AC group who underwent LT developed HCC recurrence. Conclusion: We observed a significantly lower LT probability and inferior ITT survival with DS in the AC group versus the UCSF‐DS group. Our results suggest that an upper limit in tumor burden exists beyond which successful LT after DS becomes an unrealistic goal.
Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation?
Authors: Calum D Moulton, Christine Norton, Nick Powell, Zahra Mohamedali, Christopher W P Hopkins
Journal: Gut (2019)

We read with interest Frolkis and colleagues’ recent study, in which depression was associated with increased risk of incident IBD in a large primary care database.1 While treatment of depression in IBD has been suggested to improve IBD outcomes,2 this study goes further, suggesting that assertive pharmacological treatment of depression could reduce the incidence of IBD altogether.

Despite the study’s manifest strengths, we wish to draw the authors’ attention to an important limitation of its current design that tempers its conclusions. Temporality between exposure and outcome is a key test of causality.3 This is challenging in the context of depression and IBD because their symptoms …
CORRESPONDENCE
Authors: Charles G. Irvin, David A. Kaminsky, Nicholas R. Anthonisen, Mario Castro, Nicola A. Hanania, Janet T. Holbrook, John J. Lima, Robert A. Wise
Journal: American Journal of Respiratory and Critical Care Medicine (2007)

We welcome the comments of Drs. Boysen and Block and Dr. Fer­ guson and colleagues, particularly given their substantial contribu­ tions to the literature regarding preoperative assessment for thora­ cotomy and lung resection. We were pleased to note that Boysen and Block concurred with our recommendations (I) regarding evalu­ ation of predicted postoperative FEY I as a percentage of normal value and the cautious use of postoperative irradiation ofthe medi­ astinum in patients with borderline lung function who undergo lung resection. Regarding postoperative analgesia, although the majori­ ty of our patients received intravenous narcotic infusions, we agree that regional analgesia techniques, including intrathecal and epidural narcotics, are beneficial, particularly in patients identified as high risk. While there appears no doubt that the risks of lung resection increase with worsening overall lung function, reflected in parameters such as maximal voluntary ventilation (MYY), maximal O2 uptake (Yo,max), and diffusing capacity for carbon monoxide (DLco), the challenge ofpreoperative testing is to distinguish those patients who are at unacceptable risk due to impaired lung function. In this re­ gard, preoperative evaluation that does not consider the contribu­ tion to overall function ofthe lung to be resected and the maximum amount of lung that can be resected appears to be inherently limit­ ed. Our results (I) reflect these perceptions: preoperative FEY I was not a useful predictor ofcomplications whereas predicted postoper­ ative FEY I (FEY, -ppo) was; whereas preoperativeDLco had predic­ tive power, predicted postoperative DLco (DLco-PPo) was a more powerful predictor of death and of overall complications. DLco­ ppo and FEY,-ppo are parameters that allow for the effect of lung to be resected. They require quantitative ventilation and perfusion lung scans for their calculation.
Towards Improved Decision-Making Based on Genomics in Bone Marrow Failure
Authors: Fernanda Gutierrez-Rodrigues, Carrie Diamond, Ruba Shalhoub, André Pinto, Flávia S Donaires, Diego V Clé, Luiz Guilherme Darrigo, Luiz Fernando Catto, Xing Fan, Maria del Pilar Fernandez Ibanez, Sachiko Kajigaya, Cynthia E. Dunbar, Carmem M. S. Bonfim, Danielle M. Townsley, Rodrigo T. Calado, Neal S. Young
Journal: Blood (2018)
ECG Response: March 8, 2016
Authors: Philip Podrid
Journal: Circulation (2016)

ECG Challenge: A 72-year-old man with a history of hypertension treated with atenolol and hydrochlorothiazide presents with acute renal failure resulting from a urinary tract obstruction from prostatic hypertrophy.On presentation, his heart rate is noted to be slow, and an ECG is obtained (ECG A).After admission to the hospital, an ECG is repeated (ECG B).
Surgical lung biopsy for interstitial lung disease: when considered necessary, should these be done in larger and experienced centres only?
Authors: John Hutchinson, Richard Hubbard, Ganesh Raghu
Journal: European Respiratory Journal (2019)

<b>Surgical lung biopsy for ILD: higher volume centres may offer lower mortality, but data are only suggestive – we need more research, including into lower risk alternatives to conventional biopsy, to reduce risk for patients needing diagnostic confirmation</b>http://ow.ly/OeAe30nrdMr
Executive Summary: Heart Disease and Stroke Statistics—2014 Update
Authors: Alan S. Go, Dariush Mozaffarian, Véronique L. Roger, Emelia J. Benjamin, Jarett D. Berry, Michael J. Blaha, Shifan Dai, Earl S. Ford, Caroline S. Fox, Sheila Franco, Heather J. Fullerton, Cathleen Gillespie, Susan M. Hailpern, John A. Heit, Virginia J. Howard, Mark D. Huffman, Suzanne E. Judd, Brett M. Kissela, Steven J. Kittner, Daniel T. Lackland, Judith H. Lichtman, Lynda D. Lisabeth, Rachel H. Mackey, David J. Magid, Gregory M. Marcus, Ariane Marelli, David B. Matchar, Darren K. McGuire, Emile R. Mohler, Claudia S. Moy, Michael E. Mussolino, Robert W. Neumar, Graham Nichol, Dilip K. Pandey, Nina P. Paynter, Matthew J. Reeves, Paul D. Sorlie, Joel Stein, Amytis Towfighi, Tanya N. Turan, Salim S. Virani, Nathan D. Wong, Daniel Woo, Melanie B. Turner
Journal: Circulation (2014)

The findings and conclusions of this report